Patented medicines make up approximately 47 per cent of all drug sales in Canada.

Patented Medicine Prices Review Board looks at Canadian sales of new medicines.

Annual report of the Patented Medicine Prices Review Board tabled in House of Commons.

Costs grew faster in 2021-2022 than in the previous five years.

Response to agency’s scoping paper encourages industry’s involvement in pricing review.

Once established, agency is expected to take a greater role in Canada’s drug system.

The Patented Medicine Prices Review Board (PMPRB), a federal entity that ensures patented drug prices in Canada are not …